Hubei Jumpcan Pharmaceutical Co Ltd Total Liabilities
Hubei Jumpcan Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Hubei Jumpcan Pharmaceutical Co Ltd (600566) has total liabilities worth CN¥3.19 Billion CNY (≈ $467.37 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hubei Jumpcan Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hubei Jumpcan Pharmaceutical Co Ltd (1998–2025)
Total liabilities of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2025. This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 600566 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Hubei Jumpcan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hubei Jumpcan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indian Railway Catering And Tourism Corporation Limited
NSE:IRCTC
|
India | Rs32.71 Billion |
|
Caesars Entertainment Corporation
NASDAQ:CZR
|
USA | $27.93 Billion |
|
Walsin Technology Corp
TW:2492
|
Taiwan | NT$41.28 Billion |
|
Shandong Xinchao Energy Co Ltd
SHG:600777
|
China | CN¥11.77 Billion |
|
Trex Company Inc
NYSE:TREX
|
USA | $734.05 Million |
|
PTC INDUSTRIES LTD
NSE:PTCIL
|
India | Rs4.49 Billion |
|
Allete Inc
NYSE:ALE
|
USA | $3.81 Billion |
|
Sezzle Inc.
NASDAQ:SEZL
|
USA | $223.50 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hubei Jumpcan Pharmaceutical Co Ltd balance sheet assets.
Liquidity & Leverage Metrics
Hubei Jumpcan Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Hubei Jumpcan Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Jumpcan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual total liabilities of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.07 Billion ≈ $448.89 Million |
-17.83% |
| 2024-12-31 | CN¥3.73 Billion ≈ $546.27 Million |
-21.82% |
| 2023-12-31 | CN¥4.77 Billion ≈ $698.71 Million |
+31.59% |
| 2022-12-31 | CN¥3.63 Billion ≈ $530.99 Million |
+20.96% |
| 2021-12-31 | CN¥3.00 Billion ≈ $438.99 Million |
+8.99% |
| 2020-12-31 | CN¥2.75 Billion ≈ $402.80 Million |
+7.52% |
| 2019-12-31 | CN¥2.56 Billion ≈ $374.64 Million |
+9.43% |
| 2018-12-31 | CN¥2.34 Billion ≈ $342.34 Million |
+3.48% |
| 2017-12-31 | CN¥2.26 Billion ≈ $330.82 Million |
+73.89% |
| 2016-12-31 | CN¥1.30 Billion ≈ $190.25 Million |
+48.99% |
| 2015-12-31 | CN¥872.59 Million ≈ $127.69 Million |
-17.97% |
| 2014-12-31 | CN¥1.06 Billion ≈ $155.66 Million |
+23.40% |
| 2013-12-31 | CN¥862.04 Million ≈ $126.14 Million |
+71.70% |
| 2012-12-31 | CN¥502.07 Million ≈ $73.47 Million |
+15.42% |
| 2011-12-31 | CN¥435.00 Million ≈ $63.65 Million |
+26.86% |
| 2010-12-31 | CN¥342.89 Million ≈ $50.18 Million |
+6.04% |
| 2009-12-31 | CN¥323.37 Million ≈ $47.32 Million |
-0.02% |
| 2008-12-31 | CN¥323.43 Million ≈ $47.33 Million |
+6.57% |
| 2007-12-31 | CN¥303.49 Million ≈ $44.41 Million |
+0.93% |
| 2006-12-31 | CN¥300.69 Million ≈ $44.00 Million |
+19.34% |
| 2005-12-31 | CN¥251.96 Million ≈ $36.87 Million |
+12.49% |
| 2004-12-31 | CN¥223.98 Million ≈ $32.78 Million |
+21.78% |
| 2003-12-31 | CN¥183.92 Million ≈ $26.91 Million |
+24.13% |
| 2002-12-31 | CN¥148.17 Million ≈ $21.68 Million |
+11.34% |
| 2001-12-31 | CN¥133.08 Million ≈ $19.47 Million |
+59.61% |
| 2000-12-31 | CN¥83.37 Million ≈ $12.20 Million |
+17.06% |
| 1999-12-31 | CN¥71.23 Million ≈ $10.42 Million |
-8.44% |
| 1998-12-31 | CN¥77.79 Million ≈ $11.38 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicines in China. The company offers drugs in the fields of pediatrics, respiratory system, digestive system, and gynecology. It is also involved in daily chemical product sales; and wholesale and retail pharmaceuticals. The company is headquartered in Taixing, China.